• Progressing commercialisation activities to drive revenue growth
• Secured $5.39M in matched grants to fund technology development
• Achieved US$1.8M purchase agreement with world's largest vaccine manufacturer

AnteoTech Ltd (ASX: ADO) has reported its 1H FY25 results and provided an operational update, highlighting key achievements and outlining strategies to drive continued growth. The company's revenue stage applied materials technology is unlocking opportunities in the global battery anode market and enabling affordable diagnostics. Key highlights include: Progressing commercialisation activities to drive revenue growth, with validations of the Anteo X and Ultranode products with major automakers like Mercedes-Benz; Securing $5.39M in matched grants from the Queensland Government and ARENA to fund the development of the next-generation Ultranode technology; Achieving a US$1.8M minimum purchase agreement over 5 years with the world's largest vaccine manufacturer, Serum Institute of India, for the company's AnteoBind technology; and Overhauling operations, appointing key commercial leaders, and strengthening the balance sheet to support the company's 2025 initiatives.

The company expects to deliver multiple revenue streams and commercial agreements across its clean energy and life sciences divisions in CY2025, including product sales, paid development activities, and new partnering opportunities.